EUVIMED · CrossrefJournal
Translational Breast Cancer Research
ISSN 2218-6778 · AME Publishing Company
Latest articles
Role of circulating tumor cell clusters in breast cancer
Clinical practice guidelines for prognosis and follow-up of early-stage breast cancer patients: Chinese Society of Breast Surgery (CSBrS) practice guidelines (2026 edition) Chinese Society of Breast Surgery, Chinese Society of Surgery, Chinese Medical Association
Organoids in breast cancer translational research: intersection of technologies
Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future?
Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses
The role of a national cancer registry in effective implementation and monitoring of the Global Breast Cancer Initiative (GBCI) framework in Ghana: a narrative review
Omission of breast surgery in exceptional responders after neoadjuvant chemotherapy—what are future possibilities?—a narrative review
Enhancing patient education in breast surgery: artificial intelligence-powered guidance for mastopexy, augmentation, reduction, and reconstruction
Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review
De-escalation of axillary treatment in early breast cancer—a narrative review of current trials
Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy
Breast ultrasound knobology and the knobology of twinkling for marker detection
Pathological precision diagnosis and recent advances in HER2 low and ultralow in breast cancer: a narrative review
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024
Evolution of localization methods for non-palpable breast lesions: a literature review from a translational medicine perspective
Breast surgery after neoadjuvant systemic therapy
Narrative review on advancing breast cancer treatment: harnessing the power of PD-1/PD-L1 inhibitors for improved patient outcomes
Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives
Challenges in HER2-low breast cancer identification, detection, and treatment
Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression
Androgen receptor in breast cancer and its clinical implication
Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China
Features and applications of Ehrlich tumor model in cancer studies: a literature review
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer
Psychophysical effects of 4 months of outdoor winter mountain workouts in breast cancer survivors
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy
CSCO breast cancer management guidelines 2022: Australian perspective
Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
EUVIMED